Otofarma S.P.A. engages in construction, production and distribution of custom-made hearing aids. The company provides hearing aid solutions under ENDO, CIC, and retro micro series. It also offer accessories, such as remote control, TV connector, battery charger, charger D, power bank, and remote plus application. The company is based in Naples, Italy. Otofarma S.P.A. operates as a subsidiary of Bartolomucci Holding s.r.l.…
Otofarma S.p.A., un premio per l’Eccellenza e l’Innovazione
Otofarma (BIT: OTO) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector.
The shares were at 2.240 EUR on 20 November 2026, down 52.5% over 52 weeks. Its 52-week range is 2.060 EUR to 5.240 EUR: the price is 57.3% below the high and 8.7% above the low.
At a market capitalisation of 13.32M EUR, it trades at 22.4 times trailing earnings and 56.0 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 12% for OTO.
Otofarma reports return on equity of 13.7%, an operating margin of 22.9% and revenue up 20.7% year over year.
It holds more cash than debt, a net cash position of 5.70M EUR. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 3.000 EUR is 33.9% above the current price.
No upcoming events tracked.